This week, the overall grades of three Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Emergent Biosolutions (NYSE:EBS) ratings are on the decline this week as the company earns a F (“strong sell”). Last week, it received a D (“sell”). Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. In Portfolio Grader’s specific subcategory of Sales Growth, EBS also gets an F. To get an in-depth look at EBS, get Portfolio Grader’s complete analysis of EBS stock.
Progenics Pharmaceuticals (NASDAQ:PGNX) gets weaker ratings this week as last week’s D drops to a F. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock price has fallen 25% over the past month, worse than the 2.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
Geron (NASDAQ:GERN) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Geron Corporation is a biopharmaceutical company that discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. The stock gets F’s in Equity, Cash Flow, and Sales Growth. For a full analysis of GERN stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.